Alfa Cytology identifies unique cancer-carrying genes by sequencing tumor cell genes, predicts immune presentation affinity, and then screens out unique neoantigens encoded by cancer-carrying genes. Our goal is to use neoantigens to target various cancers, such as developing neoantigen vaccines and related targeted therapies, thereby making a huge contribution to tumor immunotherapy. Alfa Cytology provides neoantigen services >.